logo
New longevity drug for dogs could extend your pet's life — and pave the way for humans to live longer too

New longevity drug for dogs could extend your pet's life — and pave the way for humans to live longer too

New York Post17-06-2025
Sit, stay… live longer?
Research shows that owning a dog can help humans live longer, healthier lives. Now, a US biotech company wants to return the favor with anti-aging drugs designed to extend the lifespan of your canine companion.
'The longevity space is crowded right now, and for good reason,' Celine Halioua, founder and CEO of Loyal, told The Post. 'We all want to figure out how to get more happy, healthy years for our loved ones —especially the furry ones.'
6 Celine Halioua is leading the push to develop drugs that extend the lives of dogs.
X/@loyalfordogs
Before launching Loyal in 2019, Halioua worked on treatments for neurodegenerative diseases in humans — conditions that, much like aging in dogs, have no true preventive medicine.
'This combination of experience sparked my mission to develop the first drug approved for healthy lifespan extension,' she said.
Good boys, great science
Loyal has three longevity drugs in the pipeline, including two that specifically target bigger breeds, which typically have much shorter lifespans.
While small dogs like Chihuahuas can live for 18 years or longer, giant breeds such as Great Danes would be lucky to make it to ten.
That's where LOY-001 and LOY-003 come in. These drugs target dogs age seven and older that weigh at least 40 pounds.
6 Loyal's drugs aim to increase and quality of life for senior dogs.
X/Celine Halioua
They work by reducing levels of insulin-like growth factor 1 (IGF-1), a hormone that fuels cell growth. Scientists believe that high levels of IGF-1 shorten the lifespan of large dogs, which can have up to 28 times more of the hormone than smaller breeds.
One version, LOY-001, is an injectable given a few times a year at the vet. The other, LOY-003, is a daily chewable pill.
Both drugs are currently in pilot studies, and Loyal is eyeing conditional FDA approval by 2027.
Loyal's third longevity drug, LOY-002, is even further along in development. The treatment targets senior dogs age 10 and up that weigh at least 14 pounds.
It's currently being tested in a large-scale clinical trial involving more than 1,200 dogs across 70 clinics, making it one of the biggest studies in veterinary history, according to Halioua.
6 Small dogs tend to have a longer lifespan than larger breeds.
X/Celine Halioua
The drug works by targeting metabolism — the complex system of chemical reactions that powers essential functions like breaking down food, producing energy and repairing cells.
As metabolism slows with age, it can lead to insulin resistance and trigger a range of health issues in both humans and dogs, including cognitive decline, osteoarthritis and cancer.
'Improving metabolic health is one of the most well-validated pathways for extending both lifespan and healthspan,' Halioua said.
'Research [shows] it can improve health and reduce the risk of age-related diseases across species — from mice to humans,' she added.
So far, things are looking paws-itive. A pilot study of 48 dogs showed no adverse effects after three months of LOY‑002.
6 Both LOY-002 and LOY-003 are administered via a daily pill.
X/Celine Halioua
Loyal previously told The Guardian it's hoping the drug could add at least one extra year to a dog's life — and they'll be healthier during that time, too.
Once it's approved, Halioua hopes LOY‑002 will become a common preventive tool, like flea and tick medication.
'We expect all dogs to benefit from its ability to protect against, and even reverse, some of the harmful effects of metabolic dysfunction,' she said.
Loyal anticipates that the drug will receive conditional approval by the FDA in 2026.
6 Loyal is aiming to enroll 1,300 dogs in it's LOY-002 study.
X/Celine Halioua
But the dogs aren't the only ones who could benefit.
'We're on track to develop the first-ever FDA-approved drug for longevity — for any species,' Halioua said.
'Dogs share our environments and develop remarkably similar age-related diseases at similar stages of life, making them valuable models for human health and scientific research,' she added.
Dogs make us healthier, too
Halioua's lifelong love of animals runs deep.
'I've always been surrounded by animals — growing up, my family had 15 pets and rehabilitated wild animals,' she said. 'My Rottweiler, Della, is always by my side and is a major influence on the work I do.'
It turns out dogs don't just bring love — they could bring health benefits as well.
Studies show that dogs can ease loneliness, stress and anxiety. One even found that just 10 minutes of petting a pooch can significantly reduce levels of cortisol, the body's main stress hormone.
6 Dogs are known for their unconditional love and companionship.
yurakrasil – stock.adobe.com
Even locking eyes with your dog gives your brain a boost. A 2009 Japanese study found that staring into their eyes raises oxytocin — the 'love hormone' linked to bonding and happiness.
Dogs might even help you live longer. A sweeping review of research from 1950 to 2019 found that dog owners consistently have a lower risk of death compared to those without pets.
It's no accident. Research shows that dog owners tend to have lower blood pressure, cholesterol and a reduced risk of heart disease. Plus, they get more exercise, which builds muscle, strengthen bones and joints and keeps weight in check.
That's no coincidence. Dog owners tend to have lower blood pressure, cholesterol, and less risk of heart disease. Plus, they're more active — walking their dogs regularly strengthens muscles, bones and joints, and helps keep weight in check.
Some research even links dog ownership to bigger brains and sharper thinking, with faster processing speed and better memory.
And here's the kicker: a major study found owning a dog lowers dementia risk — a benefit not shared by cat owners.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

SpaceX rocket to launch Amazon broadband satellites from Cape Canaveral Space Force Station
SpaceX rocket to launch Amazon broadband satellites from Cape Canaveral Space Force Station

Yahoo

timean hour ago

  • Yahoo

SpaceX rocket to launch Amazon broadband satellites from Cape Canaveral Space Force Station

In a partnership between rivals, Elon Musk's SpaceX is slated to launch a payload of Jeff Bezos' Amazon broadband satellites into low-Earth orbit during a late-night liftoff from Cape Canaveral Space Force Station. The SpaceX Falcon 9 rocket will take flight during a 1½-hour launch window extending from 2:10 a.m. to 3:38 a.m. Wednesday, July 16, a National Geospatial-Intelligence Agency navigational advisory indicates. The Falcon 9 will deploy a batch of Project Kuiper satellites for Amazon's early stage satellite internet constellation, the Space Coast Office of Tourism reported. What's more, this mission represents the first of a three-launch contract. Cape Canaveral: Is there a launch today? Upcoming SpaceX, NASA, ULA rocket launch schedule at Cape Canaveral Live FLORIDA TODAY Space Team launch coverage updates will kick off about 90 minutes before the early morning launch window opens. When SpaceX's live webcast begins about five minutes before liftoff, look for it posted below next to our countdown clock. In total, Amazon has more than 80 future launches lined up with SpaceX, United Launch Alliance, Blue Origin and Arianespace to create its $10 billion worldwide high-speed internet network, which should someday surpass 3,200 satellites. Amazon officials hope Project Kuiper will eventually compete with SpaceX's well-established Starlink constellation, which has nearly 8,000 satellites in orbit — and more than six million customers. But thus far, Amazon has only launched a combined 54 Project Kuiper satellites during two ULA missions — one on April 28, the second on June 23 — using Atlas V rockets from Cape Canaveral Space Force Station. Wednesday's SpaceX represents Project Kuiper's third launch of production satellites. On Sunday, July 13, SpaceX marked its 500 Falcon 9 mission by launching the Commercial GTO-1 mission from Cape Canaveral Space Force Station. The liftoff sent Israel's first national communications satellite, Dror 1, up into orbit. "Built by Israel Aerospace Industries, this $200M 'smartphone in space' will power Israel's strategic and civilian communications for 15 years. A bold leap for Israeli innovation!" Israel's Ministry of Foreign Affairs said in a tweet. For the latest news from Cape Canaveral Space Force Station and NASA's Kennedy Space Center, visit Another easy way: Click here to sign up for our weekly Space newsletter. Rick Neale is a Space Reporter at FLORIDA TODAY. Contact Neale at Rneale@ Twitter/X: @RickNeale1 Space is important to us and that's why we're working to bring you top coverage of the industry and Florida launches. Journalism like this takes time and resources. Please support it with a subscription here. This article originally appeared on Florida Today: Internet rivals team up: SpaceX to launch Amazon satellites into orbit

WHO Recommends 'Breakthrough' Twice-Yearly Shot for HIV Prevention
WHO Recommends 'Breakthrough' Twice-Yearly Shot for HIV Prevention

Health Line

timean hour ago

  • Health Line

WHO Recommends 'Breakthrough' Twice-Yearly Shot for HIV Prevention

The WHO issued a global recommendation for lenacapavir, a highly effective, twice-yearly injection to prevent HIV infection. The recommendation follows a recent FDA approval for the drug, which will be sold in the U.S. under the brand name Yeztugo. The twice-yearly shot showed near total effectiveness in clinical trials and could improve adherence rates compared to other PrEP medications. Experts are excited about using lenacapvir for HIV prevention, but remain cautious about the drug's affordability and accessibility. A drug used to treat some HIV infections can now be used to help prevent HIV, the virus that causes AIDS. The World Health Organization (WHO) issued a global recommendation for lenacapavir, a twice-yearly injection to help prevent HIV infections, particularly for higher-risk groups and in regions where HIV transmission remains high. The recommendation, issued on July 14 at the International AIDS Conference in Kigali, Rwanda, follows a recent Food and Drug Administration (FDA) approval for lenacapavir to prevent human immunodeficiency virus or HIV in adults and adolescents. Lenacapavir (Yeztugo) from Gilead Sciences has been shown to significantly reduce the risk of HIV infection in two phase 3 clinical trials that were funded by the company. The PURPOSE 1 and PURPOSE 2 trials, which were highly inclusive by design, showed that 99.9% of participants who received lenacapavir remained HIV negative. The side effects were also minimal, mostly pain or swelling at the injection site. Additionally, when compared to current preexposure prophylaxis or PrEP therapies, lenacapavir offered superior protection against the HIV virus. In 2024, Science magazine named the drug its 'Breakthrough of the Year.' PrEP treatments have been used in the United States to prevent HIV since 2012. These therapies generally involve daily oral medication (Truvada) or injections every two months (Apretude). The new biannual injection option offers an effective and appealing alternative for HIV prevention with less commitment. Yeztugo is the first and only twice-yearly option for HIV prevention available in the United States for those who may need or want PrEP. The FDA approval of this prevention therapy marks a silver lining amid uncertainty in HIV treatment and research. The Trump administration had recently announced federal cuts to funding for an HIV vaccine program and the elimination of federal support for clinical practice guidelines that advise doctors on how to diagnose and treat HIV. 'Yeztugo could be the transformative PrEP option we've been waiting for — offering the potential to boost PrEP uptake and persistence and adding a powerful new tool in our mission to end the HIV epidemic,' Carlos del Rio, MD, Distinguished Professor of Medicine in the Division of Infectious Diseases at Emory University School of Medicine and co-director of the Emory Center for AIDS Research in Atlanta, said in a news release on June 18. 'A twice-yearly injection could greatly address key barriers like adherence and stigma, which individuals on more frequent PrEP dosing regimens, especially daily oral PrEP, can face. We also know that, in research, many people who need or want PrEP preferred less frequent dosing,' del Rio continued. Twice-yearly shot could improve PrEP adherence rates Despite advancements in HIV treatment and prevention, in 2023, more than 100 people were diagnosed with HIV every day in the United States. A recent CDC analysis shows that up to 2.5 million U.S. adults need PrEP to prevent HIV infection. However, just over one-third of those who would benefit from the medication are prescribed it. PrEP therapies are widely available in the United States, but the medication remains underutilized due to stigma or lack of affordability, insurance, and access. Black people, African Americans, and Latin or Hispanic populations are most impacted by this disparity, as are those who reside in the Southern U.S. Experts say having a highly effective, twice-yearly PrEP option for HIV prevention could improve access for people with and without insurance and bolster adherence rates. 'Providers are excited about the approval of long-acting lenacapavir for HIV prevention since this once-every-six-month injection has been shown to have high efficacy in preventing HIV in both women and men in two large trials,' said Monica Gandhi, MD, MPH, a professor of medicine at the University of California, San Francisco. Gandhi wasn't involved in the clinical trials. 'Data from our clinic in San Francisco, which serves low income people with or at risk of HIV, and others have shown that long-acting PrEP works well for people living with HIV who have high rates of concomitant challenges such as housing insecurity and substance use where it can be difficult to take a daily oral pill for PrEP,' Gandhi told Healthline. Gandhi further noted that higher retention rates have been observed among those on long-acting PrEP with another long-acting agent, Apretude (cabotegravir), compared to oral PrEP alone. She anticipates similar improved adherence rates for those on long-acting Yeztugo (lenacapavir), both for those who have difficulty taking an oral pill or those who might prefer the convenience of a twice-yearly injection. Twice-yearly PrEP could be a 'game-changer' Within the United States, men who have sex with men, as well as heterosexual individuals with multiple partners, are considered high risk for HIV transmission. But the need for accessible HIV prevention therapies like PrEP spans the globe. According to Gilead, regulators around the world are reviewing Yeztugo for HIV prevention. For now, the United States is the only country to approve the drug. 'It's very exciting and we have a great deal of confidence in it,' William Schaffner, MD, professor of preventive medicine and infectious diseases in the Department of Health Policy at Vanderbilt University Medical Center in Nashville, said of the drug. Schaffner wasn't involved in the clinical trials. 'It could be a game-changer,' he told Healthline. 'Short of a vaccine, this is a way to efficiently prevent HIV infection in large populations that are at high risk, not only in the developed world, but potentially in the developing world also. If we have the determination, followed by the allocation of resources to reach out to populations at high risk, we can make this available,' Schaffer noted. A promising option with obstacles ahead It's unclear when Yeztugo will become available to the general U.S. population and how much it might cost out of pocket, particularly for those without health insurance. 'I don't know how quickly the company can make this available and educate practitioners about its utility, but certainly both in the public health sector — and we'll see where the resources extend to — and in private medical circumstances, we may have to wait a little while before medical insurance programs include Yeztugo in their benefits packages,' Schaffer said. Gandhi expressed concern over the drug's high cost and whether it would be covered by large health insurance companies. A corporate spokesperson for Gilead said lenacapavir could cost around $28,218 annually per person in the United States. 'We are working to make Yeztugo accessible for anyone who needs or wants it and expect to see broad insurance coverage,' the spokesperson said by email. 'We've seen high insurance coverage for existing prevention options — for example, the vast majority of consumers have a $0 copay for Descovy for PrEP in the U.S. — and we are working to ensure broad coverage for lenacapavir.' Gandhi agreed that the estimated total cost per year is similar to the total cost of other long-acting PrEP therapies, such as Apretude (cabotegravir), but noted the medication may still be out of reach for those with low socioeconomic status who rely on federal subsidies. 'These are days of austerity in healthcare, including the concerning possibility of a $700 billion cut to Medicaid which will be determined in an upcoming Senate vote, leaving the health insurance program for low-income individuals in the U.S. severely underfunded. I urge the company to reconsider their price to improve access for Americans,' Gandhi said.

The FDA Just Approved a New Blue Food Dye: This Is What It's Made Of
The FDA Just Approved a New Blue Food Dye: This Is What It's Made Of

CNET

time2 hours ago

  • CNET

The FDA Just Approved a New Blue Food Dye: This Is What It's Made Of

This year, food dyes are being put under a microscope. Following the FDA ban on Red Dye No. 3 in January, the administration has since approved three natural food dyes in its stead. Now, in addition to the FDA and Department of Health and Human Services asking food manufacturers to phase out all petroleum-based synthetic dyes from the US food supply, the FDA is asking these companies to fast-track getting rid of Red No. 3 before the 2027 deadline. To help this along, the administration just approved a new blue food dye. As the fourth color additive from natural sources approved by the FDA this year, gardenia (genipin) blue has been granted permission to be used in various foods. According to the administration, this blue dye comes from the fruit of the gardenia, a flowering evergreen. It can be used in hard and soft candy, sports drinks, ready-to-drink teas, flavored or enhanced non-carbonated water and fruit drinks and ades. "This expedited timeline underscored our serious intent to transition away from petroleum-based synthetic dyes in the food supply, said FDA Commissioner Marty Makary in a news release. "Now, by expanding the palette of available colors derived from natural sources, food manufacturers have a variety of options available that will make it easier to end their use of petroleum-based dyes." Gardenia (genipin) blue joins the red algae-based galdieria extract blue, butterfly pea flower extract and the white color calcium phosphate as 2025's new and approved natural food color additives. MichelleHow is gardenia (genipin) blue made? The FDA approved the use of gardenia (genipin) blue from a petition by the Gardenia Blue Interest Group (GBIG). According to the FDA's order, gardenia (genipin) blue is a dark purple or blue liquid made from the mature fruit of the Gardenia jasminoides Ellis plant with soy protein hydrolysate. Now, you may be thinking: Isn't soy an allergen? According to the GBIG, the soy protein allergens aren't expected to be detected in the final color additive because "unreacted protein hydrolysate is removed during manufacturing." Because no soy protein allergens will be in the final product, the GBIG is asking to be exempt from food allergen labeling. The FDA is currently reviewing this petition.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store